MDP Photo

The mission of the Georgetown University Memory Disorders Program is to prevent and treat Alzheimer's disease and related dementias by conducting innovative research, educating and training healthcare professionals and the public on research advances, and offering state-of-the-art clinical care.

MDP IN THE NEWS

The Nilotinib for Alzheimer's disease trial is now enrolling participants. Take a look at a recent interview with Dr. Turner and contact us for more information.

WE ARE ON FACEBOOK

"Like" our facebook page to stay up to date on research findings and helpful information

JOIN OUR MAILING LIST!

Would you like to receive our Fall newsletter? Sign up here to receive our newsletter either in the mail or via email. We send out two newsletters a year to everyone on our mailing list and as well invitations to our yearly fall appreciation event.

Research Studies

Here are our research studies that are currently recruiting patients.

Title Sponsor
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4) ATRI/ Eli Lilly and Company

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Biogen

DOD-ADNI: A Study of Brain Aging in Vietnam War Veterans

ATRI

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects with Mild to Moderate Alzheimer’s Disease

Georgetown University

A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease

Acadia

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

ATRI

An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease (AMARANTH)

Eli Lilly & Co

A Randomized, Double-blind, Placebo-controlled, Two-cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease

Novartis

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort

ACRIN

Check out our Research section for more information on how to participate in our clinical trials.

Make a Donation

For information about how to make a tax-deductible contribution to the Memory Disorders Program, please click here.